Physician profile
Benjamin P Schrubbe
NPI 1306895289
$14,093.78
in general payments reported to CMS, 2019-2025
66 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $1,619 · 2021: $2,436 · 2022: $2,070 · 2023: $2,248 · 2024: $1,851 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,317 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,316.65 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,653.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,634.68 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,268.73 | 2019-2025 | |
| Lilly USA, LLC | $1,072.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $910.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $625.91 | 2019-2025 | Xarelto, Spravato |
| Amgen INC. | $559.63 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $529.87 | 2019-2025 | Vaxneuvance, Gardasil 9, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.68 | 2019-2025 | Stiolto Respimat, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $456.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $444.21 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.60 | 2019-2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $302.52 | 2023-2025 | Auvelity, Sunosi |
| Novartis Pharmaceuticals Corporation | $230.85 | 2019-2022 | |
| Corcept Therapeutics | $223.89 | 2020-2021 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $208.74 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $203.73 | 2019-2025 | Trintellix |
| Antares Pharma, INC. | $194.54 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Tris Pharma INC | $168.02 | 2022-2025 | Dyanavel Xr |
| Amarin Pharma, INC. | $162.71 | 2019-2022 | |
| Corium, LLC | $141.39 | 2023-2025 | Azstarys |
| Lundbeck LLC | $123.14 | 2022-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $116.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $102.62 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $101.86 | 2019-2022 | |
| Exact Sciences Corporation | $92.71 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Shire North American Group INC | $91.77 | 2019 | |
| Allergan, INC. | $89.55 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $89.00 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $77.60 | 2019-2023 | Qelbree, Xyosted |
| Mylan Specialty L.P. | $72.71 | 2019-2024 | Yupelri |
| Tolmar, INC. | $66.37 | 2024 | |
| Phathom Pharmaceuticals, INC. | $65.92 | 2024-2025 | Voquezna |
| Seqirus USA INC | $64.39 | 2025 | Flucelvax |
| Ironshore Pharmaceuticals INC. | $60.58 | 2019-2020 | |
| Boston Scientific Corporation | $58.07 | 2025 | Watchman Access System, Wavewriter Alpha Prime 16 |
| Hikma Pharmaceuticals USA | $57.38 | 2019-2024 | Kloxxado, Ryaltris, Mitigare |
| Esperion Therapeutics, INC. | $57.17 | 2020-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $55.48 | 2020-2021 | |
| Optinose US, INC. | $51.94 | 2019-2021 | |
| Daiichi Sankyo INC. | $51.34 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.17 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $49.56 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $47.96 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $42.88 | 2020-2022 | |
| Neos Therapeutics, LP | $42.62 | 2019-2023 | Adzenys Xr-Odt |
| Sanofi-Aventis U.S. LLC | $42.24 | 2019-2020 | |
| Abbott Laboratories | $40.09 | 2023 | Freestyle Libre 2 |
| Jazz Pharmaceuticals INC. | $37.83 | 2021 | |
| Viatris Specialty LLC | $36.29 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $34.05 | 2020-2022 | |
| Organon LLC | $29.67 | 2025 | |
| Acadia Pharmaceuticals INC | $26.97 | 2025 | Daybue |
| Shield Therapeutics INC | $25.60 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.75 | 2023 | Gvoke Hypopen |
| Eisai INC. | $19.07 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.33 | 2023 | Nuzyra |
| Celgene Corporation | $17.69 | 2019 | |
| Medtronic, INC. | $17.62 | 2023 | Intellis Adaptivestim |
| Ironwood Pharmaceuticals, INC | $15.82 | 2021 | |
| Halozyme INC | $15.57 | 2023 | |
| Ibsa Pharma INC. | $14.99 | 2023 | Tirosint, Licart |
| Bausch Health US, LLC | $14.84 | 2022 | |
| Clarus Therapeutics INC. | $14.38 | 2021 | |
| Impel Pharmaceuticals INC. | $13.08 | 2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Schrubbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.